Spicer, J., Helland, Å., Carcereny, E., Arriola, E., Gomez, M. D., Trigo Perez, J. M., Thompson, J., Strauss, J., Ortega Granados, A. L., Felip, E., Schmidt, E., Chisamore, M., Madeleine, N., Rayford, A., Lorens, K., Siddiqui, A., Gabra, H., Nautiyal, J., Micklem, D., Lorens, J., & Krebs, M. (n.d.). 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. Journal for immunotherapy of cancer, 8, A221. http://access.bl.uk/ark:/81055/vdc_100144723274.0x000005